As generative AI moves toward performing increasingly consequential clinical functions, the American Medical Association (AMA) is urging the U.S. Food and Drug Administration to address a foundational question: Who is responsible for ensuring that these tools remain safe once they enter clinical practice?
The post AMA Calls for Risk-Based GenAI Oversight to Protect Patients and Support Responsible Innovation appeared first on MedCity News.
